These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37092329)

  • 1. Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis.
    Adhikari J; Hirai T; Kawakita E; Iwai K; Koya D; Kanasaki K
    J Diabetes Investig; 2023 Jul; 14(7):844-855. PubMed ID: 37092329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
    Kanasaki K; Shi S; Kanasaki M; He J; Nagai T; Nakamura Y; Ishigaki Y; Kitada M; Srivastava SP; Koya D
    Diabetes; 2014 Jun; 63(6):2120-31. PubMed ID: 24574044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.
    Spencer NY; Yang Z; Sullivan JC; Klein T; Stanton RC
    PLoS One; 2018; 13(7):e0200249. PubMed ID: 29979777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans.
    Batchu SN; Yerra VG; Liu Y; Advani SL; Klein T; Advani A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
    Kanasaki K
    Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation.
    Ide M; Sonoda N; Inoue T; Kimura S; Minami Y; Makimura H; Hayashida E; Hyodo F; Yamato M; Takayanagi R; Inoguchi T
    PLoS One; 2020; 15(2):e0228750. PubMed ID: 32032367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
    Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
    J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats.
    Aboulmagd YM; El-Bahy AAZ; Menze ET; Azab SS; El-Demerdash E
    Eur J Pharmacol; 2020 Aug; 881():173224. PubMed ID: 32454118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.
    Shi S; Srivastava SP; Kanasaki M; He J; Kitada M; Nagai T; Nitta K; Takagi S; Kanasaki K; Koya D
    Kidney Int; 2015 Sep; 88(3):479-89. PubMed ID: 25830763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
    Takashima S; Fujita H; Fujishima H; Shimizu T; Sato T; Morii T; Tsukiyama K; Narita T; Takahashi T; Drucker DJ; Seino Y; Yamada Y
    Kidney Int; 2016 Oct; 90(4):783-96. PubMed ID: 27475229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.
    Aroor AR; Habibi J; Kandikattu HK; Garro-Kacher M; Barron B; Chen D; Hayden MR; Whaley-Connell A; Bender SB; Klein T; Padilla J; Sowers JR; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2017 May; 16(1):61. PubMed ID: 28476142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
    Darsalia V; Ortsäter H; Olverling A; Darlöf E; Wolbert P; Nyström T; Klein T; Sjöholm Å; Patrone C
    Diabetes; 2013 Apr; 62(4):1289-96. PubMed ID: 23209191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model.
    Wang SC; Wang XY; Liu CT; Chou RH; Chen ZB; Huang PH; Lin SJ
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
    Kanda J; Furukawa M; Izumo N; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
    Drug Discov Ther; 2020 Nov; 14(5):218-225. PubMed ID: 33116039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
    Nakaoku Y; Saito S; Yamamoto Y; Maki T; Takahashi R; Ihara M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DPP-4 inhibitor linagliptin ameliorates imiquimod-induced psoriasis-like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF-κB inflammatory pathway.
    Shao Z; Li X; Xu X; Chen P
    Drug Dev Res; 2022 Sep; 83(6):1373-1382. PubMed ID: 35749612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP-4 inhibition by linagliptin ameliorates age-related mild cognitive impairment by regulating microglia polarization in mice.
    Zhuge F; Zheng L; Pan Y; Ni L; Fu Z; Shi J; Ni Y
    Exp Neurol; 2024 Mar; 373():114689. PubMed ID: 38199510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
    Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
    Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T; Stirban A; Terjung A; Esmaeili H; Berk A; Thiemann S; Chilton R; von Eynatten M; Marx N
    Cardiovasc Diabetol; 2017 Jan; 16(1):13. PubMed ID: 28109295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.
    Sharkovska Y; Reichetzeder C; Alter M; Tsuprykov O; Bachmann S; Secher T; Klein T; Hocher B
    J Hypertens; 2014 Nov; 32(11):2211-23; discussion 2223. PubMed ID: 25215436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.